BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27127173)

  • 21. Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases.
    Bedolla RG; Wang Y; Asuncion A; Chamie K; Siddiqui S; Mudryj MM; Prihoda TJ; Siddiqui J; Chinnaiyan AM; Mehra R; de Vere White RW; Ghosh PM
    Clin Cancer Res; 2009 Feb; 15(3):788-96. PubMed ID: 19188148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells.
    Wang Y; Kreisberg JI; Bedolla RG; Mikhailova M; deVere White RW; Ghosh PM
    Oncogene; 2007 Sep; 26(41):6061-70. PubMed ID: 17420725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear transport signals control cellular localization and function of androgen receptor cofactor p44/WDR77.
    Gu Z; Zhou L; Gao S; Wang Z
    PLoS One; 2011; 6(7):e22395. PubMed ID: 21789256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus.
    Shiota M; Yokomizo A; Masubuchi D; Tada Y; Inokuchi J; Eto M; Uchiumi T; Fujimoto N; Naito S
    Prostate; 2010 Apr; 70(5):540-54. PubMed ID: 19938016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
    Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer.
    Peng Y; Chen F; Melamed J; Chiriboga L; Wei J; Kong X; McLeod M; Li Y; Li CX; Feng A; Garabedian MJ; Wang Z; Roeder RG; Lee P
    Proc Natl Acad Sci U S A; 2008 Apr; 105(13):5236-41. PubMed ID: 18356297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells.
    Heitzer MD; DeFranco DB
    Cancer Res; 2006 Jul; 66(14):7326-33. PubMed ID: 16849583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line.
    Wang LG; Ossowski L; Ferrari AC
    Oncogene; 2004 Jul; 23(30):5175-84. PubMed ID: 15156193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.
    Yuan X; Li T; Wang H; Zhang T; Barua M; Borgesi RA; Bubley GJ; Lu ML; Balk SP
    Am J Pathol; 2006 Aug; 169(2):682-96. PubMed ID: 16877366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cells.
    Dar JA; Masoodi KZ; Eisermann K; Isharwal S; Ai J; Pascal LE; Nelson JB; Wang Z
    J Steroid Biochem Mol Biol; 2014 Sep; 143():473-80. PubMed ID: 24662325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.
    Li N; Chen M; Truong S; Yan C; Buttyan R
    Prostate; 2014 Oct; 74(14):1400-10. PubMed ID: 25132524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
    Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
    Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MEIS1 functions as a potential AR negative regulator.
    Cui L; Li M; Feng F; Yang Y; Hang X; Cui J; Gao J
    Exp Cell Res; 2014 Oct; 328(1):58-68. PubMed ID: 25158280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
    Shafi AA; Putluri V; Arnold JM; Tsouko E; Maity S; Roberts JM; Coarfa C; Frigo DE; Putluri N; Sreekumar A; Weigel NL
    Oncotarget; 2015 Oct; 6(31):31997-2012. PubMed ID: 26378018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
    Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.